Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.

Published on Sep 30, 2021in Liver International5.828
路 DOI :10.1111/LIV.15075
Sonalie Patel1
Estimated H-index: 1
Michelle T. Martin8
Estimated H-index: 8
(UIUC: University of Illinois at Urbana鈥揅hampaign),
Steven L. Flamm44
Estimated H-index: 44
(NU: Northwestern University)
Recently, we read with interest the publication by Berkan-Kawinska and colleagues which compared real world hepatitis C virus (HCV) treatment in patients with decompensated cirrhosis and compensated cirrhosis. Authors noted that use of treatment regimens including a protease inhibitor did not increase the risk of hepatic decompensation.1 We would like to present additional data, particularly regarding the use of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy in this difficult-to-cure patient population.
馃摉 Papers frequently viewed together
4 Authors (J. Llaneras, ..., Buti M)
5 Authors (Neelam Kalita, ..., Joanna Picot)
#7Evelyn Thomson (Glas.: University of Glasgow)H-Index: 135
#19Eleanor Barnes (University of Oxford)H-Index: 59
Last. William L. Irving (NUH: Nottingham University Hospitals NHS Trust)H-Index: 52
view all 18 authors...
Sustained viral response (SVR) rates for Direct Acting Antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent DAA combination primarily used for the retreatment of patients failed by DAA therapies. Here we evaluate retreatment outcomes and the effects of resistance associated substitutions (RAS) in a real-world cohort, including a large number o...
#1Aleksandra Berkan-Kawi艅ska (Medical University of 艁贸d藕)H-Index: 3
#2Anna Piekarska (Medical University of 艁贸d藕)H-Index: 12
Last. Robert Flisiak (UMB: Medical University of Bia艂ystok)H-Index: 54
view all 31 authors...
BACKGROUND AND AIMS The aim of this study was to assess the real-life effectiveness and safety of direct acting antivirals (DAAs) in patients with cirrhosis and history of hepatic decompensation compared to those with compensated cirrhosis. METHOD Data of patients treated with DAAs and included in the EpiTer-2 database (N=10,152) were collected retrospectively. The primary endpoint was sustained viral response (SVR) at 12 weeks posttreatment. Patients were also evaluated in terms of liver-relate...
#1Marc G. Ghany (NIH: National Institutes of Health)H-Index: 71
#2Timothy R. MorganH-Index: 85
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website ( disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of hepatitis C virus (HCV) infection. Utilizing a web-based system enables time...
#1J. Llaneras (Autonomous University of Barcelona)H-Index: 7
#2Mar Riveiro-Barciela (Autonomous University of Barcelona)H-Index: 17
Last. F. GeaH-Index: 12
view all 33 authors...
Abstract Background Around 5% of patients with chronic hepatitis C virus (HCV) infection treated with direct-acting antiviral (DAA) agents do not achieve sustained virological response (SVR). The currently approved retreatment regimen for prior DAA failure is a combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX), although there is little data on its use in clinical practice. The aim of this study was to analyse the effectiveness and safety of SOF/VEL/VOX in the real-world sett...
#1Marc Bourli猫reH-Index: 67
#2Stuart C. Gordon (HFHS: Henry Ford Health System)H-Index: 41
Last. S. Pianko (MHH: Hannover Medical School)H-Index: 16
view all 32 authors...
BackgroundPatients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. MethodsWe conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly assi...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.